Company Overview
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company that offers a specialized platform for precise genome editing. The firm functions within the broader healthcare sector and specifically targets the biotechnology industry, where it leverages novel CRISPR hybrid RNA-DNA technology to advance therapeutic development. The company's scale is defined by a market capitalization of $181.68M and a total of 97 employees, reflecting the typical lean organizational structure of early-stage biopharmaceutical entities. This market cap of $181.68M combined with annual revenue of $11.16M indicates a company that has secured significant investor confidence despite operating with limited revenue, suggesting a valuation heavily weighted on future potential rather than current cash flow generation. The employee count of 97 aligns with the operational requirements of a clinical-stage entity focused on high-value research and development without the overhead of a large commercial sales force.
Financial Health
The company reported revenue of $11.16M over the trailing twelve months, yet it recorded a net income of $-148,124,992 and an EBITDA of $-130,273,000, highlighting a significant disparity where operational costs and R&D expenditures far exceed current revenue generation. This massive gap between revenue and net income reveals a cost structure dominated by heavy investment in research, development, and clinical trials typical of biotechnology firms in the clinical stage. The free cash flow stands at $-69,796,752, indicating that the company is consuming cash to fund its operations and growth initiatives rather than generating surplus liquidity for immediate distribution. Such negative free cash flow implies a reliance on external capital markets or existing cash reserves to sustain financial operations until product candidates reach commercialization milestones. Analysis of the three primary margins shows a gross margin of 0.0%, an operating margin of -722.0%, and a profit margin of 0.0%, figures that underscore the intense capital intensity of the business model before economies of scale are realized. On the balance sheet, the company holds $139.34M in cash against $27.23M in debt, supported by a debt-to-equity ratio of 22.29, which suggests a leveraged position that is mitigated by a substantial cash cushion. The current ratio is reported at 5.71, indicating a highly conservative short-term liquidity position where current assets significantly exceed current liabilities, providing ample buffer for operational needs. Return on Equity is -79.0% and return on assets is -34.3%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a common characteristic of pre-revenue biotech companies investing aggressively in their pipeline.
Valuation Assessment
Valuation metrics for Caribou Biosciences, Inc. present a complex picture due to the lack of profitability, with a P/E ratio (TTM) listed as N/A and a forward P/E of -1.25, implying that traditional earnings-based valuation models are not applicable and that the market is pricing in future earnings expectations rather than current performance. The price-to-book ratio is 1.46, indicating that the market values the company at a premium of 46% over its book value, a common scenario for biotechnology firms where intangible assets and intellectual property are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 16.28 and an EV/EBITDA of -0.53 suggest the market is willing to pay a high multiple for each dollar of sales, reflecting confidence in the scalability of the genome-editing platform despite current losses. The stock price has fluctuated significantly, trading between a 52-week low of $0.66 and a 52-week high of $3.54, meaning the current price sits within a range that reflects high volatility and sensitivity to clinical trial data. With a beta of 2.55, the stock exhibits substantial price volatility relative to the broader market, moving more than twice as much as the market index, which aligns with the high-risk profile of clinical-stage biotechnology investments.
Growth & Income
The company demonstrates robust top-line expansion with revenue growth of 89.7% year-over-year, while earnings growth is N/A due to the lack of profitability, implying that revenue expansion is currently outpacing any notion of earnings growth since earnings are deeply negative. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm retains all earnings and cash flow to reinvest into research, development, and clinical trials rather than distributing income to shareholders. This reinvestment strategy is essential for clinical-stage biopharmaceutical companies that must fund expensive trial costs to advance their CRISPR genome-editing technology toward market approval. Overall, the growth and income profile of Caribou Biosciences, Inc. is characterized by rapid revenue acceleration funded entirely by cash reserves and equity financing, with no current income distribution to investors.